NKGN vs. AIM, PLUR, INAB, EVAX, INKT, ACHL, TARA, APTO, SRZN, and PMCB
Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include AIM ImmunoTech (AIM), Pluri (PLUR), IN8bio (INAB), Evaxion Biotech A/S (EVAX), MiNK Therapeutics (INKT), Achilles Therapeutics (ACHL), Protara Therapeutics (TARA), Aptose Biosciences (APTO), Surrozen (SRZN), and PharmaCyte Biotech (PMCB). These companies are all part of the "biological products, except diagnostic" industry.
NKGen Biotech (NYSE:NKGN) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.
76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 20.0% of NKGen Biotech shares are held by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
NKGen Biotech has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500.
AIM ImmunoTech received 56 more outperform votes than NKGen Biotech when rated by MarketBeat users.
In the previous week, NKGen Biotech had 5 more articles in the media than AIM ImmunoTech. MarketBeat recorded 6 mentions for NKGen Biotech and 1 mentions for AIM ImmunoTech. NKGen Biotech's average media sentiment score of 0.33 beat AIM ImmunoTech's score of 0.00 indicating that NKGen Biotech is being referred to more favorably in the media.
NKGen Biotech has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -14,337.62%. NKGen Biotech's return on equity of 0.00% beat AIM ImmunoTech's return on equity.
AIM ImmunoTech has higher revenue and earnings than NKGen Biotech.
Summary
NKGen Biotech beats AIM ImmunoTech on 9 of the 12 factors compared between the two stocks.
Get NKGen Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NKGen Biotech Competitors List
Related Companies and Tools
